The U.S. Food and Drug Administration has officially declared an end to the shortage of Novo Nordisk’s popular weight-loss and diabetes medications, Wegovy and Ozempic. This announcement will halt widespread sales of cheaper, compounded versions produced by pharmacies that capitalized on the shortage.
About the Author
